Commerce Bank Takes Position in AtriCure, Inc. $ATRC

Commerce Bank purchased a new position in AtriCure, Inc. (NASDAQ:ATRC) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 11,445 shares of the medical device company’s stock, valued at approximately $320,000.

A number of other large investors also recently modified their holdings of the company. Bank of America Corp DE raised its position in shares of AtriCure by 13.7% during the 1st quarter. Bank of America Corp DE now owns 768,561 shares of the medical device company’s stock worth $21,927,000 after purchasing an additional 92,830 shares during the last quarter. Assenagon Asset Management S.A. acquired a new stake in AtriCure in the 2nd quarter worth about $1,744,000. Rice Hall James & Associates LLC purchased a new stake in AtriCure during the 2nd quarter worth approximately $3,755,000. F m Investments LLC purchased a new stake in AtriCure during the 4th quarter worth approximately $2,872,000. Finally, Vanguard Group Inc. raised its holdings in shares of AtriCure by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 4,903,755 shares of the medical device company’s stock valued at $193,993,000 after acquiring an additional 62,861 shares during the last quarter. 99.11% of the stock is currently owned by institutional investors.

AtriCure Trading Down 1.5%

ATRC opened at $48.54 on Friday. The firm has a market capitalization of $2.47 billion, a price-to-earnings ratio of 231.15 and a beta of 1.20. The company’s 50 day simple moving average is $37.89 and its two-hundred day simple moving average is $32.26. AtriCure, Inc. has a 1-year low of $25.36 and a 1-year high of $49.98. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.22 and a quick ratio of 3.19.

AtriCure (NASDAQ:ATRC) last posted its quarterly earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share (EPS) for the quarter. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.The business had revenue of $153.60 million during the quarter, compared to analyst estimates of $151.80 million. During the same period in the prior year, the business earned ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Analysts expect that AtriCure, Inc. will post 0.29 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. Citigroup restated a “market outperform” rating on shares of AtriCure in a research report on Tuesday, July 21st. Raymond James Financial set a $52.00 price target on AtriCure in a research report on Tuesday, July 21st. Canaccord Genuity Group raised their price objective on AtriCure from $53.00 to $55.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. Zacks Research lowered AtriCure from a “strong-buy” rating to a “hold” rating in a report on Monday, August 24th. Finally, Wall Street Zen cut shares of AtriCure from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 2nd. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, AtriCure presently has an average rating of “Moderate Buy” and an average target price of $49.89.

Insider Activity at AtriCure

In other AtriCure news, insider Vinayak Doraiswamy sold 6,000 shares of the company’s stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $38.88, for a total value of $233,280.00. Following the completion of the sale, the insider directly owned 86,511 shares in the company, valued at $3,363,547.68. This represents a 6.49% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Justin J. Noznesky sold 6,182 shares of the firm’s stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $38.80, for a total value of $239,861.60. Following the completion of the sale, the insider directly owned 100,219 shares of the company’s stock, valued at $3,888,497.20. This trade represents a 5.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 53,616 shares of company stock valued at $2,149,994 in the last three months. Company insiders own 4.00% of the company’s stock.

AtriCure Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.